SCHEMBL30749097

SCHEMBL30749097

COc1cc(N2CCOCC2)ccc1N1C(=O)C(C)(C)c2c(Cl)nc(Cl)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42
KMT2A Q03164 1/20 0.42
INSR P06213 4/20 0.41
ALK Q9UM73 3/20 0.41
GAA P10253 2/20 0.41
ALOX15 P16050 1/20 0.41
LRRK2 Q5S007 2/20 0.40
PTK2 Q05397 1/20 0.39
PIK3CA P42336 1/20 0.39
CHEK1 O14757 1/20 0.39
TNK2 Q07912 1/20 0.39
DCLK1 O15075 1/20 0.38
MAPK7 Q13164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749157 0.82 PIK3CA (0.47) MAPTL3MBTL1SMN1; SMN2ALDH1A1HPGD
SCHEMBL30748904 0.80 RAD51 (0.42) SMN1; SMN2ALDH1A1HPGD
SCHEMBL30748903 0.79 ALOX15 (0.35) ALOX15
SCHEMBL30749100 0.71 PRKDC (0.42) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL30748783 0.70 AGXT (0.34) MAPTL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL30749140 0.70 MAPT (0.39) MAPTL3MBTL1SMN1; SMN2ALDH1A1MEN1
SCHEMBL30748801 0.69 ELANE (0.37) MAPTL3MBTL1SMN1; SMN2ALDH1A1KMT2A
SCHEMBL223337 0.67 LGMN (0.61) MAPTALDH1A1HPGDMEN1POLB
SCHEMBL30749007 0.67 ELANE (0.44) L3MBTL1ALDH1A1POLBKMT2ANPSR1
Hydrochloric Acid SCHEMBL375344 0.66 LGMN (0.59) MAPTALDH1A1HPGDMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPT 3029/4885L3MBTL1 517/4885SMN1; SMN2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.